1.
Int Clin Psychopharmacol
; 14(3): 193-5, 1999 May.
Article
in English
| MEDLINE
| ID: mdl-10435775
ABSTRACT
The effectiveness of adding moclobemide to antipsychotic treatment in schizophrenic patients with prominent negative symptoms was examined. Eleven chronic schizophrenic patients had their regular antipsychotic treatment augmented by the addition of moclobemide 450 mg/day for 8 weeks. A significant improvement was seen on the Positive and Negative Syndrome Scale (PANSS) negative factor and for the Scale for the Assessment of Negative Symptoms (SANS) scores, PANSS total score, PANSS general factor score and Hamilton Depression Scale scores. Positive symptoms were not altered. Moclobemide augmentation may ameliorate negative, depressive and general symptoms in schizophrenia.
Subject(s)
Antipsychotic Agents/therapeutic use , Benzamides/therapeutic use , Monoamine Oxidase Inhibitors/therapeutic use , Schizophrenia/drug therapy , Benzamides/adverse effects , Drug Synergism , Female , Humans , Male , Middle Aged , Moclobemide , Monoamine Oxidase Inhibitors/adverse effects , Psychiatric Status Rating Scales , Schizophrenic Psychology
2.
Biol Psychiatry
; 40(1): 75-7, 1996 Jul 01.
Article
in English
| MEDLINE
| ID: mdl-8780859
Subject(s)
Fluvoxamine/therapeutic use , Melatonin/blood , Schizophrenia/drug therapy , Selective Serotonin Reuptake Inhibitors/therapeutic use , Adult , Biomarkers , Chronic Disease , Dose-Response Relationship, Drug , Drug Tolerance , Female , Humans , Male , Psychiatric Status Rating Scales , Schizophrenia/blood
3.
Am J Psychiatry
; 152(7): 1098, 1995 Jul.
Article
in English
| MEDLINE
| ID: mdl-7793452
4.
Schizophr Res
; 16(1): 77-9, 1995 Jul.
Article
in English
| MEDLINE
| ID: mdl-7547649